Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Amgen
Amgen
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Synaffix enters ADCs agreement with Amgen
Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments
Ingredients
Therapeutic: tezepelumab for asthma
An estimated 2.5 million people around the world are thought to have uncontrolled asthma and many do not respond adequately to currently available preventer medicines
Research & Development
Oxford Nanopore gets cash injection
Biotech company Amgen has announced a £50m (US$66m) equity investment in the UK-based company developing real-time genetic sequencing technology
Media
GlobalData publishes analysis of top 25 global pharma companies
The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Media
GlobalData names top 25 global pharma companies by market cap
The performance highlights of the top 25 publicly traded global pharma companies for the year 2017 have been confirmed in the latest research from GlobalData
Research & Development
Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies
Immatics to receive $30 million upfront and potentially more than $1 billion in milestone payments plus royalties
Research & Development
Biocartis and Amgen sign a RAS biomarker testing collaboration in Europe
Biocartis, an innovative molecular diagnostics company, has signed a new collaboration agreement with Amgen, a leading biotechnology company
Subscribe now